DNA-Based PCSK9 Treatment

How Does the DNA-Based PCSK9 Treatment Lower Cholesterol?

PCSK9 is produced mainly by the liver and promotes the breakdown of LDL receptors on liver cells. These receptors normally clear LDL cholesterol from the bloodstream. Reducing PCSK9 therefore allows more receptors to remain available, a mechanism already validated by approved PCSK9-targeting medicines.

The new approach uses a specially designed DNA-based molecule to interfere with PCSK9 production or activity. Researchers reported that their most effective candidate reduced PCSK9 protein by 87% and LDL cholesterol by nearly 50% in the experimental setting. Those findings demonstrate biological activity, but they do not yet show that the treatment prevents heart attacks or strokes in patients.

How Could This Treatment Differ From Existing PCSK9 Medicines?

Approved PCSK9 inhibitors such as evolocumab are monoclonal antibodies administered by injection, while inclisiran is a small interfering RNA medicine that reduces PCSK9 production in liver cells. Both approaches can produce substantial LDL reductions when added to appropriate background treatment.

A DNA-based molecule might eventually offer advantages involving manufacturing, stability, dosing frequency or treatment cost. However, those possibilities must be tested rather than assumed. Researchers will need to determine how the molecule is delivered to the liver, how long its effect lasts and whether it causes unintended immune responses or off-target effects.

Could a DNA Treatment Replace Statins for High Cholesterol?

Statins have decades of clinical evidence showing that lowering LDL cholesterol reduces cardiovascular events. Current cholesterol guidelines generally recommend statins first for patients who need medication, with non-statin therapies added when LDL remains above an individualized target or when statins are not tolerated.

The reported LDL reduction makes the DNA candidate scientifically promising, especially for people who cannot reach adequate control with existing options. Before it could enter routine care, however, phased human trials would need to evaluate dosing, safety, durability and LDL lowering, followed by studies capable of showing whether treatment improves cardiovascular outcomes. Patients should not stop prescribed cholesterol medication because of these early findings.